Search Hotels in Daly City

Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases

December 16, 2021

From Alpine Immune Sciences, Inc. and Horizon Therapeutics plc

Few questions stump Tim Walbert. But the Horizon Therapeutics CEO is still working to answer one of them from his son.

This Biotech CEO Is Trying To Cure His Son's Rare Disease

December 09, 2021

Horizon Therapeutics plc Makes $100,000 Seed Donation to Support Fundraising Efforts to Renovate Emmett Till’s Home into a Museum and Theater

December 02, 2021

Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD...

Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021

December 08, 2021

Via Benzinga

Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List

December 02, 2021

Horizon Therapeutics plc Provides Academic Scholarships to Help Economically Disadvantaged Students in Ireland Further Their STEM Education

December 01, 2021

Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead.

7 Drug Stocks to Buy Now While They’re Still on Sale

November 30, 2021

Via InvestorPlace

Topics Supply Chain

Exposures COVID-19 Supply Chain

New Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficacy of UPLIZNA® (inebilizumab-cdon) in Patients Previously Treated with Rituximab for Neuromyelitis Optica Spectrum Disorder (NMOSD)

November 22, 2021

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021

November 19, 2021

Via Benzinga

Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week with New Educational and Community Building Initiative

November 15, 2021

New Real-World Data Show High Rate of Patient Adherence to TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)

November 12, 2021

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis

November 09, 2021

Horizon Therapeutics plc to Participate in Upcoming Investor Conferences

November 08, 2021

Stock Market Rally Keeps Running On Tesla, Nvidia, Fed Decision, Jobs Report: Weekly Review

November 05, 2021

But the Nasdaq is starting to look extended.

Topics Bonds Economy Stocks

Exposures COVID-19 Debt Markets Interest Rates

Horizon Therapeutics plc Receives Top Workplace Awards in Chicago and San Francisco

November 05, 2021

Results from PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) in Kidney Transplant Recipients with Uncontrolled Gout Presented as Part of American Society of Nephrology (ASN) Kidney Week

November 04, 2021

According to Benzinga Pro, during Q3, Horizon Therapeutics (NASDAQ:HZNP) earned $331.54 million, a 142.86% increase from the preceding quarter. Horizon Therapeutics also posted a...

Horizon Therapeutics's Return On Capital Employed Insights

November 04, 2021

Via Benzinga

Horizon Pharma plc (HZNP) Q3 2021 Earnings Call Transcript

November 03, 2021

HZNP earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Exposures Financial

CFO Retirement Plan Undoes Horizon Therapeutics Stock After Beat-And-Raise

November 03, 2021

Chief Financial Officer Paul Hoelscher will retire on May 16.

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering

Topics Retirement

Exposures Pension

November 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...

Via Benzinga

Topics Retirement

Exposures Pension

Horizon Therapeutics plc Announces Chief Financial Officer Succession Plan

November 03, 2021

Horizon Therapeutics plc Reports Record Third-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance

November 03, 2021

New Data Being Presented at American College of Rheumatology Convergence 2021 Highlight Horizon’s Commitment to Improving Outcomes for People Living with Uncontrolled Gout

November 01, 2021

MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA® (pegloticase injection) with Methotrexate

October 25, 2021

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

Horizon Therapeutics plc Named to Newsweek’s List of the Most Loved Workplaces for 2021

October 22, 2021

Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)

October 21, 2021

New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)

October 13, 2021

On Tuesday, Beam Therapeutics stock reached an key performance benchmark, seeing its RS Rating jump to 92, up from 88 the day before.

Beam Therapeutics Stock Flashes Renewed Technical Strength

October 12, 2021